{
    "Trade/Device Name(s)": [
        "CLUNGENE Fentanyl Home Test Cassette",
        "CLUNGENE Fentanyl Test Cassette"
    ],
    "Submitter Information": "Hangzhou Clongene Biotech Co., Ltd.",
    "510(k) Number": "K242802",
    "Predicate Device Reference 510(k) Number(s)": [
        "K233417"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NGL"
    ],
    "Summary Letter Date": "September 14, 2024",
    "Summary Letter Received Date": "September 17, 2024",
    "Submission Date": "September 13, 2024",
    "Regulation Number(s)": [
        "21 CFR 862.3650"
    ],
    "Regulation Name(s)": [
        "Opiate Test System"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Fentanyl"
    ],
    "Specimen Type(s)": [
        "Human Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Competitive binding",
        "Lateral flow immunochromatographic assay",
        "Antigen antibody immunochemistry"
    ],
    "Methodologies": [
        "Qualitative immunoassay"
    ],
    "Submission Type(s)": [
        "Cassette",
        "Reagent",
        "Accessory",
        "Package insert",
        "Dropper"
    ],
    "Document Summary": "FDA 510(k) summary for CLUNGENE Fentanyl Home/Test Cassette, a lateral flow immunoassay for qualitative fentanyl detection in human urine.",
    "Indications for Use Summary": "Qualitative detection of fentanyl in human urine at a cut-off concentration of 1.0 ng/mL; provides preliminary results requiring confirmatory testing by alternative chemical methods; for in vitro diagnostic use only.",
    "fda_folder": "Toxicology"
}